This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yajima, N. Articles by Tanaka, R. Search for Related Content PubMed PubMed Citation Articles by Yajima, N. Articles by Tanaka, R.

Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma

Authors' Affiliations: ¹ Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan and Departments of ² Neurosurgery and ³ Immunology and Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume, Fukuoka, Japan

Requests for reprints: Ryuya Yamanaka, Department of Neurosurgery, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata, Japan 951-8585. Phone: 81-25-227-0651; Fax: 81-25-223-5287; E-mail: ryaman{at}bri.niigata-u.ac.jp.

Purpose: The primary goal of this phase I study was to assess the safety and immunologic responses of personalized peptide vaccination for patients with advanced malignant glioma.

Experimental Design: Twenty-five patients with advanced malignant glioma (8 grade 3 and 17 grade 4 gliomas) were evaluated in a phase I clinical study of a personalized peptide vaccination. For personalized peptide vaccination, prevaccination peripheral blood mononuclear cells and plasma were provided to examine cellular and humoral responses to 25 or 23 peptides in HLA-A24⁺ or HLA-A2⁺ patients, respectively; then, only the reactive peptides (maximum of four) were used for in vivo administration.

Results: The protocols were well tolerated with local redness and swelling at the injection site in most cases. Twenty-one patients received more than six vaccinations and were evaluated for both immunologic and clinical responses. Increases in cellular or humoral responses specific to at least one of the vaccinated peptides were observed in the postvaccination (sixth) samples from 14 or 11 of 21 patients, respectively. More importantly, significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Clinical responses were 5 partial responses, 8 cases of stable disease, and 8 cases of progressive disease. The median overall survival for patients with recurrent glioblastoma multiforme in this study (n = 17) was 622 days.

Conclusions: Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients.

This article has been cited by other articles:

				A. O. Weinzierl, C. Lemmel, O. Schoor, M. Muller, T. Kruger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingel, H.-G. Rammensee, et al. Distorted Relation between mRNA Copy Number and Corresponding Major Histocompatibility Complex Ligand Density on the Cell Surface Mol. Cell. Proteomics, January 1, 2007; 6(1): 102 - 113. [Abstract] [Full Text] [PDF]

				H. Uemura, K. Fujimoto, M. Tanaka, M. Yoshikawa, Y. Hirao, S. Uejima, K. Yoshikawa, and K. Itoh A Phase I Trial of Vaccination of CA9-Derived Peptides for HLA-A24-Positive Patients with Cytokine-Refractory Metastatic Renal Cell Carcinoma. Clin. Cancer Res., March 15, 2006; 12(6): 1768 - 1775. [Abstract] [Full Text] [PDF]

				W. Debinski Personalized, Multivalent, and More Affordable: The Globalization of Vaccines Clin. Cancer Res., August 15, 2005; 11(16): 5663 - 5664. [Full Text] [PDF]